NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Clinical Advances and Unanswered Questions in Narcolepsy," Lindsay McCullough, MD, discusses how clinical understanding of narcolepsy has evolved, where major diagnostic and treatment advances have occurred, and where important gaps remain. McCullough, assistant professor of medicine and associate program director for the sleep medicine fellowship at Rush University, reflects on progress in defining narcolepsy subtypes, the growing role of orexin biology, and how recent research in 2025 has reshaped conversations around disease-modifying approaches. The discussion also explores emerging links between sleep disorders and neurodegenerative disease, common misconceptions that continue to delay diagnosis, and how clinician education can improve recognition, safety, and long-term management of patients with narcolepsy. Looking for more Sleep Disorder discussion? Check out the NeurologyLive® Sleep Disorder clinical focus page. Episode Breakdown: 1:05 – Advances and remaining gaps in the clinical understanding of narcolepsy 2:30 – How narcolepsy care and research meaningfully evolved throughout 2025 4:50 – Sleep disorders, neurodegeneration, and what clinicians should watch for 6:50 – Neurology News Minute 8:50 – Persistent myths that delay diagnosis and affect clinical decision-making 12:30 – How lived experience shapes holistic, patient-centered narcolepsy care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Mood, Behavior, and Quality of Life in Parkinson Disease," Sneha Mantri, MD, MS, Chief Medical Officer at the Parkinson’s Foundation, discusses how mood and behavioral symptoms shape the lived experience of people with Parkinson disease across the disease course. Mantri, a practicing movement disorders specialist with extensive training and experience, explains why depression and anxiety often precede motor symptoms, how these issues evolve with cognitive change, and why they remain key drivers of quality of life. Mantri reviews commonly used screening tools – including the PHQ-2/9, Geriatric Depression Scale, GAD-7, and emerging measures like the HOPE questionnaire – emphasizing their role in opening deeper clinical conversations. She also highlights Parkinson’s Foundation initiatives that support both clinicians and patients, from PD Health at Home programming to team-based care models. The conversation concludes with ongoing challenges, including cultural barriers to mental health care, access limitations, and the continued need for true mental health parity in Parkinson disease management. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:10 – How mood and behavior symptoms shape Parkinson disease quality of life 5:30 – How conversations about mental health in Parkinson disease have evolved 9:25 – Screening tools and practical assessment strategies for mood and anxiety 13:40 – Neurology News Minute 15:50 – Foundation and community initiatives supporting mood and behavior care 19:50 – Remaining gaps, cultural barriers, and mental health parity challenges The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children’s Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Origins of the study, need to pursue more standardized care in IESS 4:40 – Reasons behind treatment variability after first and second-line options 8:00 – What research is needed to guide sequencing and standardize care 12:05 – Neurology News Minute 14:30 – What makes IESS studies difficult and how infrastructure can improve 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "NEALS 2025: Takeaways That Matter for ALS Care," ALS experts Jinsy Andrews, MD, MSc, and James Berry, MD, MPH, reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for ALS. They discuss format changes that elevated lightning science, the expanding gene therapy pipeline, and a growing slate of NEALS-affiliated trials. The conversation highlights updates from the HEALEY Platform Trial, the MY-MATCH biomarker-guided precision trial, SOD1 program data, and new antisense and viral vector therapies aimed at sporadic ALS. They also explore the impact of Act for ALS on trial access, the ALL ALS biospecimen repository, and NIH-supported expanded access cohorts. The discussion closes with insights on combination therapy strategies, genetic subtypes, presymptomatic enrollment, and how new collaborations, digital endpoints, and infrastructure advances are shaping momentum heading into 2026. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:05 – Reflections on meeting highlights and NEALS rebranding into a global network 5:00 – Notable NEALS-affiliated trials and promising new mechanisms in ALS care 12:45 – Combination therapy strategies and future approaches in ALS research 15:20 – Neurology News Minute 18:00 – Expanding clinical trial access for rare and genetic ALS subtypes 22:10 – Building momentum and expectations for the 2026 NEALS Annual Meeting The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation BTK Inhibitor Fenebrutinib Meets Primary End Points in Phase 3 Trials for Both Relapsing and Primary Progressive MS  Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. Following the 2025 Alzheimer's Association International Conference (AAIC), Rebecca Edelmayer, PhD, outlines the Alzheimer’s Association’s first clinical practice guidelines for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer’s disease within specialized care. She explains the guideline mission, how tests were evaluated for accuracy, and when BBMs should serve as triage versus confirmatory tools relative to CSF and PET. Edelmayer details current scope limits (cognitively impaired patients in specialty settings), cautions against overextending to primary care or unimpaired populations, and previews the education roll-out—executive summaries, micro-learning modules, and shared decision-making resources. She closes with research priorities: stronger peer-reviewed reporting, broader validation across diverse populations and settings, and building an equitable pathway that leverages BBMs to speed accurate diagnosis and treatment access. Looking for more Alzheimer & dementia discussion? Check out the NeurologyLive® Alzheimer & dementia clinical focus page. Episode Breakdown: 1:05 – Understanding the purpose and mission behind new blood-based biomarker guidelines 2:05 – Key recommendations and defining triage vs confirmatory blood-based biomarker use 3:15 – Clinical precautions and where blood-based biomarkers are appropriate today 5:30 – Neurology News Minute 7:45 – Educating clinicians on implementing BBMs in specialty care 10:15 – Research priorities to strengthen evidence and ensure equity The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Building Safer, Smarter, and More Personalized Epilepsy Care," Orrin Devinsky, MD, discusses major areas of progress and ongoing challenges in epilepsy care. Devinsky, a professor in the departments of neurology, neurosurgery, and psychiatry at NYU Grossman School of Medicine, reflects on how the treatment landscape has evolved in recent years, including advances in medication, awareness of SUDEP, and patient counseling. Devinsky also weighs in on the current treatment hierarchy for antiepileptic drugs and whether first-line therapeutic strategies should change. Additional discussion touches on the state of gene therapy development, the need for greater research in disease prevention, the implications of GLP/GIP agents in neurological care, and how neurodevelopmental management is advancing for pediatric patients with epilepsy. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 0:55 – How epilepsy care has evolved and where progress has been made 5:30 – Whether first-line therapy choices for epilepsy should be re-evaluated 8:35 – Why gene therapy progress has been slower than expected in epilepsy 12:05 – Neurology News Minute 14:10 – What areas of epilepsy research deserve greater attention and funding 17:10 – How GLP/GIP agents could intersect with neurological and epilepsy care 20:00 – How clinicians can better address neurodevelopmental challenges in patients with epilepsy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neflamapimod Advances to Phase 3 Trial in Dementia With Lewy Bodies After Positive RewinD-LB Results FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "ECTRIMS 2025 Meeting Highlights and Clinical Takeaways," Daniel Ontaneda, MD, PhD, neurologist at Cleveland Clinic’s Mellen Center for MS, shared his reflections from the 2025 ECTRIMS Congress, held September 24-26, in Barcelona, Spain. He discussed the significance of the updated MS diagnostic criteria, which generated immediate research applications and clinician discussion early in the meeting. Ontaneda also highlighted the growing emphasis on precision medicine and individualized treatment approaches, including extended-interval dosing strategies for B-cell therapies. In addition, he reviewed new therapeutic developments such as BTK inhibitors, CAR-T therapies, and remyelination research, noting both promising and disappointing data. Finally, he spoke on how ECTRIMS continues to expand beyond MS, with more presentations dedicated to NMOSD, MOGAD, and other autoimmune neurological conditions, reflecting the evolving landscape of neuroimmunology. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page. Episode Breakdown: 1:00 – Overall impressions of ECTRIMS 2025, highlighting diagnostic updates, precision medicine, and late-breaking trial results 4:10 – Expanding focus on individualized care, especially interval-adjusted dosing strategies for B-cell therapies 7:50 – Neurology News Minute 9:50 – Insights on emerging therapeutic approaches including BTK inhibitors, CAR-T therapies, and remyelination strategies 14:35 – Growing attention toward NMOSD, MOGAD, and other autoimmune conditions within neuroimmunology discussions The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment," Michael Okun, MD, neurologist, author of The Parkinson Plan, and medical advisor for the Parkinson’s Foundation, discusses the urgent need for global access to levodopa, the gold-standard treatment for Parkinson disease. He outlines the consequences of delayed or unavailable treatment worldwide, including worsening outcomes and unnecessary disability. Okun highlights lessons from global HIV drug distribution that can inform equitable levodopa access, emphasizing the importance of tailoring strategies to local economies and healthcare systems. Additionally, he breaks down key components of The Parkinson Plan, including prevention, research priorities, amplifying patient and caregiver voices, and rethinking care models to better address the world’s fastest growing neurodegenerative disorder. Finally, he explains how the book can serve as a resource not only for clinicians, but also for patients, families, and policymakers. Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page. Episode Breakdown: 1:00 – Consequences of delayed or unavailable levodopa treatment for patients worldwide 2:40 – How universal levodopa access could change care in low-resource settings 5:15 – Lessons from global HIV drug distribution for equitable levodopa delivery 7:00 – Neurology News Network 8:35 – Key pillars of The Parkinson Plan and rethinking Parkinson’s care models The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special edition of Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d’Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations. For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Episode Breakdown: 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care 6:05 – Major clinical insights and takeaways from phase 3 SPACE trial 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses 15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:00 – Why consensus guidelines were needed for gene therapy in DMD 2:10 – Top-line clinical considerations from the published recommendations 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity 6:30 – Neurology News Network 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care 12:00 – How these recommendations may shape the future of DMD treatment The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Global survey findings on epilepsy transition of care 2:10 – Key considerations for students with epilepsy entering college 3:50 – Ensuring continuity of care during transition into adulthood 5:45 – Neurology News Minute 7:30 – Common challenges and strategies to overcome them 9:30 – Final thoughts on back-to-school care and global survey insights The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic. Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page. Episode Breakdown: 1:00 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology 4:05 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used 6:20 – Neurology News Minute 8:45 – How nonmotor symptoms in Parkinson’s (fatigue, constipation, sleep) are managed with lifestyle strategies 12:30 – Approaching therapeutic communication and expectation-setting with patients and families The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025 IHL-42X to Enter Phase 3 Trials for Obstructive Sleep Apnea Following Positive Phase 2 Data FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care. Looking for more dementia and Alzheimer disease discussion? Check out the NeurologyLive® Dementia and Alzheimer disease clinical focus page. Episode Breakdown: 1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk 2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6 6:00 – What clinicians should know about patient risk and genotype testing 8:00 – Neurology News Minute 10:10 – Clinical implications of the updated label, including risk-benefit conversations 13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FDA approvals of STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 ( ) for the acute and preventive treatment of migraine. Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility. For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine Episode Breakdown: 1:10 – Overview of DHE, patient suitability, and STS101’s place in treatment 6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101 10:20 – The expanding migraine toolbox and need for clinician education 15:10 – CT-132’s first-in-class status and clinical trial data 16:25 – Clinical use of CT-132 as an add-on preventive 19:30 – The knowledge gap on digital therapeutics and educating the neurology community 23:00 – Future directions and hopes for expanded CT-132 research Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joyce Lee-Iannotti, MD, PhD, division chief of both the Stroke Center and the Comprehensive Sleep Center at Barrow Neurological Institute, discusses her presentation from the 2025 SLEEP Annual Meeting focused on the glymphatic system’s role in stroke. She outlines the science behind this brain-cleansing pathway, its dependence on sleep quality, and how its dysfunction may worsen outcomes in both ischemic and hemorrhagic stroke. Lee-Iannotti also details practical, evidence-backed strategies for optimizing glymphatic clearance—from sleep posture and sleep apnea treatment to emerging pharmacologic options like orexin antagonists. In addition, she highlights major gaps in clinician awareness and offers calls to action for improving sleep assessments in stroke care. Looking for more Sleep disorders discussion? Check out the NeurologyLive® Sleep disorders clinical focus page. Episode Breakdown: 1:00 – Overview of the glymphatic system and its relevance in stroke care 2:55 – Evidence linking sleep quality and glymphatic activity in stroke prevention and recovery 7:40 – Neurology News Minute 10:05 – Potential interventions: pharmacologic and nonpharmacologic approaches to enhance glymphatic function 13:10 – Raising clinical awareness of sleep’s role in stroke and neurologic disease management The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Grants Priority Review, Sets PDUFA Date for Hunter Syndrome Treatment Tividenofusp Alfa FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk Exablate Neuro Gains FDA Approval for Staged Bilateral Focused Ultrasound in Advanced Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted therapies, highlighting ongoing research in disease-modifying treatments and n-of-1 trials, especially for ultra-rare epilepsies. Additionally, Sullivan explores how the clinical trial landscape is evolving—emphasizing the need for biomarkers, innovative trial design, and better tools for seizure monitoring to improve outcomes in these complex pediatric epilepsies. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Key differences in phenotype and diagnosis between Dravet syndrome and LGS 3:00– The evolution of genetic testing and how it’s improved Dravet diagnosis and outcomes 5:25 – Opportunities and limitations in scaling genetic testing more broadly 6:35 – Neurology News Minute 8:45 – Research pipelines: disease-modifying therapies, n-of-1 trials, and future directions 10:20 – Innovations in clinical trial design and the need for better seizure monitoring and biomarkers The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:00 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy 3:00– Key design considerations for conducting a registrational phase 3 cell therapy trial 5:25 – Trial structure, eligibility criteria, and ongoing patient recruitment 6:35 – Neurology News Minute 8:45 – Significance of reaching phase 3 with a cell therapy in Parkinson disease 10:20 – Future role of cell therapy within the Parkinson disease treatment landscape 12:10 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent Obicetrapib from Phase 3 BROADWAY Trial Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "World MS Day: Raising Awareness, Evolving Care, and Empowering Patients," Taylor Hess, MD, a multiple sclerosis specialist at the Michigan Institute for Neurological Disorders (MIND), shares insights in recognition of World MS Day. She reflects on the importance of raising global awareness for MS, the need for equitable care, and the evolving focus of research and treatment. Dr. Hess discusses underrecognized symptoms like fatigue and cognitive dysfunction, and emphasizes the value of the upcoming diagnostic criteria update in enabling earlier intervention. She highlights key research priorities—including progressive MS, symptom management, and remyelination—and speaks to the importance of holistic, lifestyle-informed care. Finally, she shares advice for clinicians on how to communicate a new MS diagnosis with empathy, clarity, and empowerment. Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page. Episode Breakdown: 1:00 – Significance of World MS Day and the importance of global MS awareness 2:05– Commonly recognized vs overlooked MS symptoms in patient care 3:10 – Transitioning to updated MS diagnostic criteria and the need for global provider education 4:15 – Neurology News Minute 6:30 – Research priorities: progressive MS, symptom management, and remyelination strategies 7:35 – The role of lifestyle, risk factor control, and holistic care in MS management 8:50 – Communicating MS diagnosis with empathy, support, and resource guidance The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves First Autoinjector Form of DHE for Acute Migraine and Cluster Headache FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Refining TSC Care: Phenotyping, Clustering, and Clinical Impact," Ajay Gupta, MD, director of the Tuberous Sclerosis Program at Cleveland Clinic, discusses recently published research that used unsupervised clustering to group over 900 patients with tuberous sclerosis complex (TSC) into four clinically meaningful phenotypic clusters. He outlines the distinct traits of each cluster—ranging from tumor risk to cognitive impairment—and explains how variant-specific genetic data helped reinforce these categories. Gupta, who also serves as a professor of neurology at the Cleveland Clinic Lerner School of Medicine, also explores the clinical value of these findings for surveillance planning, early intervention, and future therapeutic trials. He emphasizes that while overlap between clusters exists, this approach lays essential groundwork for precision care and more targeted research in TSC. Looking for more epilpesy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Study goals and the shift from genotype-to-phenotype toward phenotype-to-genotype mapping 2:40– Overview of the 4 main phenotypic clusters identified in the TSC population 8:05 – Genetic domain associations and their impact on clinical monitoring and treatment 11:50 – Neurology News Minute 14:45 – Understanding overlap between clusters and avoiding overprediction in clinical settings 17:00 – Implications for future surveillance strategies and precision candidate selection in TSC trials The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA AdComm Plans to Review Investigational Cell Therapy Deramiocel for DMD Cardiomyopathy Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment Microbiome-Targeting Therapy MaaT033 Continues to Show Promise in Final Phase 1 Readout Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in launching clinical trials that now include this historically excluded population. Head also addressed the challenges in distinguishing developmental delay from early dementia symptoms, the potential role of anti-amyloid therapies, and how non-pharmacological interventions like sleep apnea treatment may contribute to cognitive preservation. She emphasized the importance of equitable research participation, clinician education, and understanding patient priorities—like independence and respect—when supporting individuals with Down syndrome and their families. Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page. Episode Breakdown: 1:00 – Overview of the ABC-DS initiative and the growing inclusion of Down syndrome in Alzheimer research 2:00– Current state of clinical trials and progress in therapeutic development for this population 3:30 – Evolution of outcome assessments tailored for individuals with Down syndrome 5:40 – Challenges in distinguishing Down syndrome traits from signs of early dementia 7:40 – Clinician educations needs and improving access to specialized care 9:00 – Neurology News Minute 11:00 – Eligibility and considerations for anti-amyloid therapies in Down syndrome 13:35 – Research gaps, co-occurring conditions, and the importance of reaching underserved populations 16:40 – Top priorities from patients and families: independence, inclusion, and respect in care settings The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.